Tirzepatide can reduce appetite, meaning the wish to eat. What did people notice, and which harms did studies find?

What changes did people notice as weight came off?

Tirzepatide can reduce hunger, which can make smaller meals feel enough. This page explains daily changes people reported and known treatment risks. Many described less hunger during the opening weeks or months. Thoughts about food took up less of their day.

Feeling sick was the problem mentioned most often during treatment. An increase in medicine could make sickness worse for a time. Constipation, loose stools, and soreness around the shot also occurred. Your symptoms can't be predicted from another person's experience.

Treatment studies found extra illness in the gallbladder and its drainage tubes. Doctors also consider the thyroid warning, which followed animal tests. Rats and mice developed tumours while receiving treatment in those tests. The same tumour risk hasn't been established in people.

Patient interviews describe experiences during studies with medical care. Personal research-use reports below come from outside those treatment studies. The accounts don't establish how shots were obtained or supervised. The safety section gives stronger findings from published treatment studies.

What can personal accounts tell you about everyday life?

These are personal accounts from people reporting research use of tirzepatide. The reports don't establish where shots came from or who supervised care. These aren't findings from a study comparing assigned treatments. Trials haven't checked the changes these people described.

Patient interviews and reports after wider public use are identified below. These accounts can't tell you how often a change happens overall. People who speak up may differ from people who stay silent. A personal account also can't prove that medicine caused the change.

Did food thoughts become less pressing? People often said meals and snacks occupied less of their attention. Some described such little hunger that eating slipped their minds. In separate SURMOUNT patient interviews, 79 to 91% named reduced appetite as a benefit. Those percentages came from different interview groups, rather than everyone receiving treatment.

Did tiredness ease as weight fell? Separate patient interview groups gave figures of 62 to 79% for improved energy. Some personal accounts described two to four weeks of tiredness after starting. Eating less may help explain that early tiredness while treatment begins. These accounts don't prove why anyone felt more energetic afterward.

Did people feel more confident? The different groups interviewed at study end gave figures of 47 to 55%. Those patients described greater confidence or a more positive mood. Other personal reports linked weight loss with less depression. None proves that tirzepatide itself caused the improvement in mood.

Did people describe better blood tests? Some reported lower sugar within a few months of beginning treatment. Others described better cholesterol, the blood fat measured in a test. Some said their doctors reduced the insulin amount they needed. Treatment trials proved sugar benefits, but didn't check each of these accounts.

Did nights become more restful? Some people found falling asleep easier and felt rested on waking. Snoring was less noticeable for some; others said snoring had stopped. Your doctor can consider such changes alongside other sleep problems. These personal reports don't establish that the medicine improved sleep.

Did less weight mean less joint pain? People with substantial weight loss described less knee, hip, or lower-back pain. Some said walking and other movement became easier as well. Nearly half in one survey described less discomfort in their joints. Their individual accounts haven't been confirmed by a trial.

Whose reports described feeling sick? Personal research-use accounts and reports after public use put sickness at roughly 25 to 50%. That figure doesn't come from the patient interview groups above. People described the worst sickness a week or two after increases. Some described less sickness during the following two to four weeks.

Did bowel habits keep changing? Some research-use accounts described loose stools coming after days of constipation. Loose stools could then give way to constipation once again. Slower movement of food may help explain those changes during treatment. Trials haven't confirmed the reported easing of these bowel problems.

What did people say about sore skin? Personal accounts described redness, itching, bruising, or tenderness near the shot. The soreness could start within hours after medicine was given. Mild trouble usually lasted two to five days in these reports. Those timings haven't been confirmed by comparing assigned study treatments.

Did the scales sometimes stop moving? Personal reports described weeks with little change in weight readings. Doctors also see pauses during weight loss, including during treatment. A pause doesn't tell you how much more weight might fall. A treatment study hasn't confirmed these particular accounts of weight-loss pauses.

Did favourite foods become unpleasant? Some accounts described a metal taste or another change in taste. Food that once tasted good could become hard to enjoy. Some people said taste improved after early weeks or steadier treatment. These accounts don't tell us how often taste changes occur.

Did lost weight come with less strength? Some people doing strength exercise said they couldn't manage as much. Study scans attributed 25 to 30% of lost weight to tissue besides fat. Muscle forms part of that tissue, though the scans didn't measure these people's strength. The accounts of weakness aren't proof of what caused each person's trouble.

When did people report hair shedding? Some personal accounts put the start three to six months into treatment. In trials, 4 to 5% lost hair, compared with 1% receiving placebo. Placebo is treatment without tirzepatide, allowing doctors to compare the groups. The reported delay before shedding came from accounts, rather than that trial comparison.

Most accounts described loose hairs, rather than bare patches on the scalp. People reported hair returning within six to twelve months after shedding. A trial hasn't confirmed that recovery time for these individuals.

Did some burps smell of eggs? Accounts linked unpleasant burps to food remaining longer in the stomach. Reports after public use put egg-smelling burps at roughly 3 to 5%. Reporting alone can't give you a firm chance of this problem. A trial hasn't checked those particular accounts against a comparison group.

What harm does your medical team watch for?

Published studies and safety reports describe the concerns below. The prescribing label explains which risks matter during medical care. Your illnesses and other medicines can alter those risks. A prescriber considers the treatment amount alongside possible harm.

Why can stomach trouble end treatment? Medicine increases often bring feeling sick, vomiting, or changed bowel habits. These problems may settle once the amount becomes steadier. A review found more stomach trouble than with placebo ^[10]. Placebo contains none of the tested medicine, allowing a comparison.

A safety report examined when reported problems began after starting treatment ^[11]. Half began within 16 days, and most within the first three months. Most caused mild or moderate trouble, though sickness often ended treatment.

Which thyroid risks rule out treatment? The thyroid gland in your neck helps control energy use. FDA's strongest label warning followed tumours in treated rats and mice ^[6]. Larger amounts or longer treatment made those animal tumours more likely. Those tests don't prove the same risk in people.

Medullary thyroid carcinoma is one particular cancer of the thyroid. A history of that cancer rules out treatment, including a relative's history. Multiple Endocrine Neoplasia syndrome type 2 also rules out treatment; children can inherit the illness, which causes gland tumours. A safety review says the cancer risk remains unproven in people ^[13].

Can the pancreas become swollen and painful? Inflammation means swelling and irritation; the pancreas is the insulin-making gland. Nine trials couldn't settle whether treatment increased this illness ^[8]. The paper's 95% confidence range, showing uncertainty, allowed either higher or lower risk. That range shows the uncertainty, rather than anyone's personal chance of illness.

A separate study followed people who had already had pancreas inflammation. Over five years, fewer repeat attacks occurred among tirzepatide patients ^[14]. Doctors compared similar people, but chance didn't assign their treatment. The finding therefore doesn't prove that tirzepatide prevented another attack.

These findings neither establish added risk nor rule the problem out. Cases remain a warning on the prescribing label for treatment. Your doctor still considers pancreas illness when weighing benefits against harm.

Did gallbladder illness become more likely? The gallbladder holds fluid that helps your body digest fat. A review of nine studies in 9,871 people found extra gallbladder or drainage-tube illness ^[8]. The 95% confidence range still supported added risk despite the uncertainty. Those figures don't give an individual patient's chance of becoming ill.

Another review, covering 12 trials, also found extra risk ^[15]. Quick weight loss can lead to gallstones, which fits the findings. Both reviews give doctors reason to consider gallbladder trouble during care.

Which medicines add to the risk of low sugar? Tirzepatide mainly prompts more insulin when blood sugar rises. Low sugar is less likely with tirzepatide by itself. Low sugar becomes more likely when insulin or certain diabetes tablets are added ^[6]. The label describes reducing the other medicine when these treatments are combined.

Reports after public use have included episodes of low sugar. A SURPASS review in older adults also found this combined effect ^[16]. Your doctor considers all the diabetes medicines together because low sugar can harm you.

Why does the operation team ask about these shots? Tirzepatide slows food leaving the stomach, so meals may remain longer. Doctors found leftover food during examinations inside the stomach ^[17]. Sedation means medicine makes you sleepy; anesthesia puts you to sleep for an operation. Both weaken protection against food coming up and entering the lungs.

Reviewers discuss fasting, meaning a longer time without food before an operation. An ultrasound shows the stomach using sound waves, revealing any leftover food. Medicines might also help food move onward before the procedure. The operation team decides, since the actual chance of harm remains uncertain.

What did scans find about muscle loss? SURMOUNT-1 scans attributed about 25% of lost weight to tissue besides fat ^[18]. Muscle was part of that tissue, though not all of it. A review put muscle at 28% of weight loss in its middle result ^[19]. Half the results were higher, and half were lower.

Another review likened the tissue amount lost to aging for a decade ^[20]. That didn't mean patients became as weak as someone a decade older. The authors discussed strength exercise as a possible way to preserve muscle. Effects on daily strength remain uncertain, so your movement matters alongside weight.

Can vomiting or diarrhea harm the kidneys? Severe or lasting stomach trouble can leave the body short of water. Water loss can injure kidneys, particularly with certain other medicines ^[13]. Water tablets and some blood-pressure medicines add to that concern. Large studies haven't found extra kidney injury overall with tirzepatide.

Why can birth control pills become less reliable? Slower stomach emptying can change when swallowed medicines reach the bloodstream. Birth control pills may then protect less well against pregnancy. The label highlights starting treatment and increases in medicine amount ^[6][17]. The label discusses birth control that doesn't depend on a swallowed pill.

What happened after the medicine stopped? SURMOUNT-4 patients changed to placebo regained 14.0% by week 88 ^[9]. Patients continuing tirzepatide lost still more weight during the study. After semaglutide or tirzepatide stopped, a review found average regain of 9.69 kilograms ^[21]. Its 95% confidence range showed uncertainty about exactly how much returned.

The finding was returning weight, rather than a lasting unchanged loss. Returning weight was linked to worsening sugar and heart-health results ^[22]. Regain can therefore affect health as well as the scale reading.

What does the comparison of treatment stops tell you? Three studies compared tirzepatide with dulaglutide, another medicine for diabetes. Tirzepatide's stopping rate for unwanted effects was 32% higher than dulaglutide's ^[23]. That's an increase relative to the other medicine's stopping rate. The comparison alone doesn't tell you how common stopping was overall.

Most people tolerated treatment, though stomach trouble accounted for many early stops. A safety report most often listed the wrong medicine amount being given ^[11]. The finding doesn't distinguish too much from too little, or establish who made the error. Reporting alone can't tell you how often such errors occur.

Can hair return after extra shedding? Hair shedding has been reported with tirzepatide and similar medicines ^[24]. Rapid weight loss and fewer nutrients may help explain the problem. Direct damage from tirzepatide hasn't been established as the cause. Shedding often settles once weight becomes steadier during care.

What led from early Tirzepatide tests to medical care?

2018: Researchers first reported tirzepatide under its early name, LY3298176 ^[1]. The medicine copies GIP and GLP-1, hormones carrying messages after meals. Its 39-amino-acid chain joins the small pieces also found in proteins. A fatty attachment slows the medicine's removal from the blood.

The mouse tests found greater sugar and weight falls than GLP-1 treatment alone. The first human tests, called phase 1, involved 142 people ^[1]. Medicine remained long enough to support shots given each week. Cell tests found hormone responses that could prompt insulin release ^[2].

SURPASS examined type 2 diabetes, while SURMOUNT examined excess weight. Direct comparisons found greater sugar or weight benefits than semaglutide ^[3][5]. May 2022 brought approval for treating type 2 diabetes in adults. November 2023 brought approval for weight care in adults meeting the rules.

Another approval covered sleep apnea when obesity was also present in adults. Sleep apnea interrupts breathing repeatedly during sleep, causing brief pauses. SURMOUNT-OSA supported that treatment use ^[25]. Your doctor still weighs the benefits against possible unwanted effects.

Further studies examined heart failure alongside obesity in adults ^[26]. The heart could squeeze normally but had trouble filling between beats. Other work studied fatty liver with inflammation, meaning swelling and irritation, and scarring ^[27]. Another long study asked about heart health and related illness ^[28].